Low dose rate teletherapy: updated tumour response.
This report presents an update of tumour response experience in patients with locally advanced head and neck cancer treated on the low dose rate teletherapy project at the Mater Misericordiae Hospital, Newcastle. Long-term progression-free survival figures are disappointing in all dose rate/total dose groupings and offer little encouragement that an improvement in therapeutic ratio can be achieved for head and neck cancer patients using teletherapy apparatus adjusted to treat at low and intermediate dose rates.
Denham
J W
JW
Radiation Oncology Department, Mater Misericordiae Hospital, Newcastle, New South Wales, Australia.
Hamilton
C S
CS
Simpson
S A
SA
O'Brien
M
M
D002588:Cesium Radioisotopes / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004307:Dose-Response Relationship, Radiation; D006258:Head and Neck Neoplasms / Q000453:epidemiology / Q000532:radiotherapy*; D006801:Humans; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage
D002588:Cesium Radioisotopes